Cancer Protocol

Ivermectin

Nobel Prize parasite therapy, now studied in oncology research

Discovered in the 1970s by Satoshi Ōmura and William Campbell. Approved in 1981 for parasitic disease, including river blindness.

Lab and animal studies report slowed tumor growth, reduced invasion, cancer-cell death, and possible synergy with chemotherapy. Models have included breast, colorectal, leukemia, and lung tumors. Human evidence is limited. These uses are experimental, not approved cancer indications.

Fenbendazole

Veterinary parasite medicine studied in cancer models

Used since the 1970s in animals for intestinal worms. It blocks parasite nutrient uptake and damages microtubules.

Lab and animal studies report slower cancer-cell growth, tumor shrinkage in models, and possible help with some chemotherapy. Models have included colorectal, lung, breast, and leukemia. Not an FDA-approved cancer therapy.

TUDCA

Liver support

Included to support the liver during the protocol and help handle metabolic stress sometimes called “die-off.” Supportive care only, not a cancer treatment.

Doxycycline

Antibiotic for many infections

Used for infections of the skin, lungs, and urine, and for malaria prevention. Research commentary discusses possible effects on cancer stem-like cell energy use and tissue-invasion enzymes. That use is experimental and not approved for cancer.